Company intelligence / Profile preview

Hanxin Pharmaceutical Technology

Nanjing, Jiangsu, China

Ownership: Private
Employees: ~250
Development stage: Other

Overview

Hanxin has more than 100 developed projects for clients, including two Class 1 new drugs in Phase I clinical trials, 21 DMF submissions, and four finished products approved by FDA for clients. Current pipeline includes a Phase 1 program for infantile spasms and an IND-stage insulin aspart biosimilar for diabetes.

Therapeutic areas: EndocrinologyHematologyPulmonologyOtherNeurology
Modalities: Small moleculePeptidesRecombinant proteinBiosimilarHormoneMonoclonal antibody
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Hanxin Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hanxin Pharmaceutical Technology.

Explore the full profile